272 related articles for article (PubMed ID: 17892982)
21. Atenolol versus Losartan in Marfan's Syndrome.
Treasure T; Pepper J; Mohiaddin R
N Engl J Med; 2015 Mar; 372(10):978-9. PubMed ID: 25738682
[No Abstract] [Full Text] [Related]
22. Atenolol versus Losartan in Marfan's Syndrome.
Ziganshin BA; Mukherjee SK; Elefteriades JA
N Engl J Med; 2015 Mar; 372(10):977-8. PubMed ID: 25738681
[No Abstract] [Full Text] [Related]
23. Atenolol versus Losartan in Marfan's Syndrome.
Lacro RV; Dietz HC; Mahony L
N Engl J Med; 2015 Mar; 372(10):980-1. PubMed ID: 25738680
[No Abstract] [Full Text] [Related]
24. Rationale and design of a randomized clinical trial (Marfan Sartan) of angiotensin II receptor blocker therapy versus placebo in individuals with Marfan syndrome.
Detaint D; Aegerter P; Tubach F; Hoffman I; Plauchu H; Dulac Y; Faivre LO; Delrue MA; Collignon P; Odent S; Tchitchinadze M; Bouffard C; Arnoult F; Gautier M; Boileau C; Jondeau G
Arch Cardiovasc Dis; 2010 May; 103(5):317-25. PubMed ID: 20619242
[TBL] [Abstract][Full Text] [Related]
25. Racial and ethnic differences in response to treatment for Marfan syndrome.
Ayers R; Kelleman M; Iannucci G; McCracken C; Oster ME
Cardiol Young; 2021 Dec; 31(12):1991-1998. PubMed ID: 33845931
[TBL] [Abstract][Full Text] [Related]
26. The effects of losartan versus beta-blockers on cardiovascular protection in marfan syndrome: A systematic review and meta-analysis.
Kang YN; Chi SC; Wu MH; Chiu HH
J Formos Med Assoc; 2020 Jan; 119(1 Pt 1):182-190. PubMed ID: 31003918
[TBL] [Abstract][Full Text] [Related]
27. Meta-analysis Examining the Usefulness of Angiotensin Receptor blockers for the Prevention of Aortic Root Dilation in Patients With the Marfan Syndrome.
Al-Abcha A; Saleh Y; Mujer M; Boumegouas M; Herzallah K; Charles L; Elkhatib L; Abdelkarim O; Kehdi M; Abela GS
Am J Cardiol; 2020 Aug; 128():101-106. PubMed ID: 32650901
[TBL] [Abstract][Full Text] [Related]
28. Correspondence regarding: Distinct effects of losartan and atenolol on vascular stiffness in Marfan syndrome by Bhatt et al.
O'Rourke MF; Adji A; Weber T
Vasc Med; 2016 Feb; 21(1):70. PubMed ID: 26669325
[No Abstract] [Full Text] [Related]
29. [Study of the efficacy and safety of losartan versus atenolol for aortic dilation in patients with Marfan syndrome].
Forteza A; Evangelista A; Sánchez V; Teixidó G; García D; Sanz P; Gutiérrez L; Centeno J; Rodríguez-Palomares J; Cortina J; García-Dorado D
Rev Esp Cardiol; 2011 Jun; 64(6):492-8. PubMed ID: 21561700
[TBL] [Abstract][Full Text] [Related]
30. Angiotensin II blockade and aortic-root dilation in Marfan's syndrome.
Brooke BS; Habashi JP; Judge DP; Patel N; Loeys B; Dietz HC
N Engl J Med; 2008 Jun; 358(26):2787-95. PubMed ID: 18579813
[TBL] [Abstract][Full Text] [Related]
31. [Aortic root dilatation rate in pediatric patients with Marfan syndrome treated with losartan].
Mariucci E; Guidarini M; Donti A; Lovato L; Wischmeijer A; Angeli E; Gargiulo GD; Picchio FM; Bonvicini M
G Ital Cardiol (Rome); 2015 Dec; 16(12):690-5. PubMed ID: 26667946
[TBL] [Abstract][Full Text] [Related]
32. Of Marfan's syndrome, mice, and medications.
Bowen JM; Connolly HM
N Engl J Med; 2014 Nov; 371(22):2127-8. PubMed ID: 25405389
[No Abstract] [Full Text] [Related]
33. Pediatric Heart Network Trial of Losartan vs. Atenolol in Children and Young Adults with Marfan Syndrome: Impact on Prescription Practices.
Robertson DM; Truong DT; Cox DA; Carmichael HL; Ou Z; Minich LL; Williams RV; Selamet Tierney ES
Pediatr Cardiol; 2023 Mar; 44(3):618-623. PubMed ID: 35902413
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of Marfan Syndrome Aortic Root Dilation by Losartan: Role of Angiotensin II Receptor Type 1-Independent Activation of Endothelial Function.
Sellers SL; Milad N; Chan R; Mielnik M; Jermilova U; Huang PL; de Crom R; Hirota JA; Hogg JC; Sandor GG; Van Breemen C; Esfandiarei M; Seidman MA; Bernatchez P
Am J Pathol; 2018 Mar; 188(3):574-585. PubMed ID: 29433732
[TBL] [Abstract][Full Text] [Related]
35. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome.
Habashi JP; Judge DP; Holm TM; Cohn RD; Loeys BL; Cooper TK; Myers L; Klein EC; Liu G; Calvi C; Podowski M; Neptune ER; Halushka MK; Bedja D; Gabrielson K; Rifkin DB; Carta L; Ramirez F; Huso DL; Dietz HC
Science; 2006 Apr; 312(5770):117-21. PubMed ID: 16601194
[TBL] [Abstract][Full Text] [Related]
36. Influence of Aortic Stiffness on Aortic-Root Growth Rate and Outcome in Patients With the Marfan Syndrome.
Selamet Tierney ES; Levine JC; Sleeper LA; Roman MJ; Bradley TJ; Colan SD; Chen S; Campbell MJ; Cohen MS; De Backer J; Heydarian H; Hoskoppal A; Lai WW; Liou A; Marcus E; Nutting A; Olson AK; Parra DA; Pearson GD; Pierpont ME; Printz BF; Pyeritz RE; Ravekes W; Sharkey AM; Srivastava S; Young L; Lacro RV;
Am J Cardiol; 2018 May; 121(9):1094-1101. PubMed ID: 29631804
[TBL] [Abstract][Full Text] [Related]
37. Beta-blockers for preventing aortic dissection in Marfan syndrome.
Koo HK; Lawrence KA; Musini VM
Cochrane Database Syst Rev; 2017 Nov; 11(11):CD011103. PubMed ID: 29110304
[TBL] [Abstract][Full Text] [Related]
38. Retrospective analysis of the effect of angiotensin II receptor blocker versus β-blocker on aortic root growth in paediatric patients with Marfan syndrome.
Mueller GC; Stierle L; Stark V; Steiner K; von Kodolitsch Y; Weil J; Mir TS
Heart; 2014 Feb; 100(3):214-8. PubMed ID: 24270746
[TBL] [Abstract][Full Text] [Related]
39. Cardiovascular characteristics in Marfan syndrome and their relation to the genotype.
De Backer J
Verh K Acad Geneeskd Belg; 2009; 71(6):335-71. PubMed ID: 20232788
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
